IMVT
Immunovant, Inc. NASDAQ Listed Jun 21, 2019$38.10
+7.81%
vs $35.34
Mkt Cap $5.8B
52w Low $14.69
100.0% of range
52w High $38.10
50d MA $30.19
200d MA $24.83
P/E (TTM)
-13.7x
EV/EBITDA
—
P/B
8.2x
Debt/Equity
0.0x
ROE
-41.9%
P/FCF
-15.3x
RSI (14)
68.60
ATR (14)
$1.60
Beta
0.67
50d MA
$30.19
200d MA
$24.83
Avg Volume
2.3M
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
320 West 37th Street · New York City, NY 10018 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | BMO | -0.60 | -0.73 | -21.7% | 26.29 | +15.3% | +35.3% | -4.0% | +0.1% | -0.9% | -1.2% | — |
| Feb 6, 2026 | BMO | -0.72 | -0.61 | +15.3% | 27.05 | +2.4% | +1.6% | -2.9% | -2.8% | -1.2% | +0.4% | — |
| Nov 10, 2025 | BMO | -0.72 | -0.73 | -1.4% | 23.37 | +0.0% | -2.1% | +2.4% | -2.6% | +4.0% | +2.4% | — |
| Aug 11, 2025 | BMO | -0.69 | -0.60 | +13.0% | 14.76 | +0.6% | +3.0% | +4.5% | -4.3% | +0.1% | +0.3% | — |
| May 29, 2025 | BMO | -0.71 | -0.64 | +10.3% | 14.89 | -0.8% | -0.3% | +3.8% | +0.2% | -0.6% | +4.4% | — |
| Feb 6, 2025 | BMO | -0.73 | -0.76 | -4.1% | 20.36 | +0.0% | +0.2% | -4.4% | -0.9% | -0.6% | +3.3% | — |
| Nov 7, 2024 | BMO | -0.60 | -0.74 | -23.3% | 29.93 | -0.1% | +2.4% | +1.6% | -6.0% | -1.3% | -2.9% | — |
| Aug 6, 2024 | BMO | -0.53 | -0.60 | -13.2% | 27.85 | +0.3% | -3.1% | +4.2% | +3.9% | +1.5% | +0.5% | — |
| May 29, 2024 | BMO | -0.43 | -0.52 | -20.9% | 29.57 | -6.3% | -10.7% | -3.9% | -0.7% | +0.1% | +1.5% | — |
| Feb 12, 2024 | BMO | -0.43 | -0.36 | +16.3% | 36.69 | -2.3% | +0.6% | +2.4% | +0.0% | -1.8% | +1.0% | — |
| Nov 9, 2023 | BMO | -0.47 | -0.45 | +4.3% | 31.31 | +1.7% | +4.2% | +0.5% | +6.6% | -2.1% | -1.5% | — |
| Aug 10, 2023 | BMO | -0.45 | -0.57 | -26.7% | 22.32 | +0.5% | +0.7% | -5.4% | -3.4% | +0.6% | -5.1% | — |
| May 22, 2023 | AMC | -0.43 | -0.46 | -7.0% | 23.75 | +0.6% | -6.4% | -4.7% | -0.6% | -0.1% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $26.55 | $26.89 | +1.3% | +3.3% | -0.3% | +7.1% | -2.6% | -0.9% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.49 | $27.50 | +0.0% | -2.9% | -2.8% | -1.2% | +0.4% | +2.1% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $27.05 | $27.69 | +2.4% | +1.6% | -2.9% | -2.8% | -1.2% | +0.4% |
| Jan 8 | Truist | Maintains | Hold → Hold | — | $26.73 | $26.32 | -1.5% | -1.6% | -1.1% | -0.8% | +1.4% | +4.5% |
| Jan 6 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $24.97 | $25.83 | +3.4% | +3.7% | +3.2% | -1.6% | -1.1% | -0.8% |
| Dec 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $26.42 | $26.73 | +1.2% | -1.6% | +2.3% | +1.4% | -3.0% | +1.9% |
| Sep 30 | JP Morgan | Maintains | Overweight → Overweight | — | $16.06 | $15.88 | -1.1% | +0.4% | +1.4% | +2.4% | +1.0% | -2.1% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.70 | $16.58 | -0.7% | -3.5% | +6.3% | -4.5% | +0.2% | -1.2% |
| Aug 12 | BofA Securities | Maintains | Buy → Buy | — | $14.76 | $14.85 | +0.6% | +3.0% | +4.5% | -4.3% | +0.1% | +0.3% |
| Aug 12 | JP Morgan | Maintains | Overweight → Overweight | — | $14.76 | $14.85 | +0.6% | +3.0% | +4.5% | -4.3% | +0.1% | +0.3% |
| Jul 28 | UBS | Maintains | Neutral → Neutral | — | $16.95 | $17.14 | +1.1% | -1.1% | -0.7% | -0.2% | -3.2% | -2.3% |
| Apr 22 | UBS | Downgrade | Buy → Neutral | — | $14.46 | $14.41 | -0.3% | -1.5% | +1.4% | +4.3% | -2.3% | +4.8% |
| Mar 20 | BofA Securities | Maintains | Buy → Buy | — | $18.88 | $18.64 | -1.3% | +4.3% | -0.3% | -1.0% | -6.4% | -1.6% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $18.88 | $18.64 | -1.3% | +4.3% | -0.3% | -1.0% | -6.4% | -1.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.79 | $17.41 | -7.3% | +0.5% | +4.3% | -0.3% | -1.0% | -6.4% |
| Mar 10 | Guggenheim | Maintains | Buy → Buy | — | $20.02 | $19.89 | -0.6% | +1.4% | -3.4% | -2.5% | -1.7% | +3.9% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.41 | $20.65 | +1.2% | -4.4% | -0.9% | -0.6% | +3.3% | +2.4% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $20.41 | $20.65 | +1.2% | -4.4% | -0.9% | -0.6% | +3.3% | +2.4% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.36 | $20.36 | +0.0% | +0.2% | -4.4% | -0.9% | -0.6% | +3.3% |
| Jan 15 | BofA Securities | Maintains | Buy → Buy | — | $22.88 | $23.35 | +2.1% | +6.6% | -2.5% | +0.3% | -1.1% | -1.5% |
| Jan 3 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $25.19 | $24.52 | -2.7% | -1.5% | -0.7% | +0.0% | -4.1% | -0.6% |
| Dec 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $26.25 | $26.33 | +0.3% | -2.2% | +0.8% | -0.4% | +1.2% | -1.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.93 | $29.91 | -0.1% | +2.4% | +1.6% | -6.0% | -1.3% | -2.9% |
| Oct 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.61 | $29.74 | +0.4% | +1.4% | -0.3% | +1.6% | -3.2% | -3.0% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.02 | $27.65 | -1.3% | +1.7% | -0.2% | +3.8% | -0.8% | +4.2% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.44 | $31.65 | +0.7% | -5.5% | -2.3% | -0.7% | +2.8% | -0.8% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $29.64 | $29.99 | +1.2% | +0.5% | +1.2% | +2.4% | -2.7% | +3.7% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $26.98 | $27.29 | +1.1% | +4.2% | +3.9% | +1.5% | +0.5% | +1.2% |
| Jun 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.39 | $25.21 | -0.7% | -0.7% | +0.1% | +1.5% | -0.7% | -1.0% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.57 | $27.70 | -6.3% | -10.7% | -3.9% | -0.7% | +0.1% | +1.5% |
| May 30 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $29.57 | $27.70 | -6.3% | -10.7% | -3.9% | -0.7% | +0.1% | +1.5% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $32.20 | $32.42 | +0.7% | -3.0% | +0.7% | +3.5% | -0.6% | -2.2% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.18 | $40.41 | +11.7% | +8.1% | +6.1% | +6.5% | -1.4% | -2.8% |
| Dec 21 | BofA Securities | Maintains | Buy → Buy | — | $36.18 | $40.41 | +11.7% | +8.1% | +6.1% | +6.5% | -1.4% | -2.8% |
| Dec 1 | UBS | Maintains | Buy → Buy | — | $39.13 | $39.35 | +0.6% | +3.6% | +0.6% | -2.2% | -2.3% | +3.2% |
| Nov 15 | Truist | Maintains | Buy → Buy | — | $34.97 | $34.97 | +0.0% | -2.1% | -1.5% | +0.3% | -0.1% | -2.5% |
| Oct 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.80 | $34.64 | +2.5% | +3.6% | -3.0% | +0.9% | -2.4% | -1.5% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.80 | $34.64 | +2.5% | +3.6% | -3.0% | +0.9% | -2.4% | -1.5% |
| Oct 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.41 | $37.53 | +0.3% | +0.9% | -0.9% | -1.3% | -2.9% | -2.3% |
| Oct 13 | UBS | Upgrade | Neutral → Buy | — | $35.28 | $36.78 | +4.3% | +6.0% | +0.9% | -0.9% | -1.3% | -2.9% |
| Oct 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.23 | $35.72 | -1.4% | +2.8% | -0.1% | -1.5% | -3.7% | +6.0% |
| Sep 27 | Raymond James | Upgrade | Market Perform → Outperform | — | $39.96 | $42.50 | +6.4% | -1.1% | +0.7% | -3.5% | -9.8% | -1.0% |
| Sep 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $39.96 | $42.50 | +6.4% | -1.1% | +0.7% | -3.5% | -9.8% | -1.0% |
| Sep 27 | Citigroup | Maintains | Buy → Buy | — | $39.96 | $42.50 | +6.4% | -1.1% | +0.7% | -3.5% | -9.8% | -1.0% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $20.28 | $32.29 | +59.2% | +97.0% | -1.1% | +0.7% | -3.5% | -9.8% |
| Sep 22 | Guggenheim | Maintains | Buy → Buy | — | $21.25 | $21.27 | +0.1% | -4.0% | -0.5% | +97.0% | -1.1% | +0.7% |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $21.81 | $21.98 | +0.8% | +0.6% | -2.1% | -4.1% | +3.2% | -4.0% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $20.58 | $20.63 | +0.2% | -0.0% | -1.7% | -1.0% | +0.2% | +4.8% |
| Aug 16 | Truist | Maintains | Buy → Buy | — | $20.52 | $20.62 | +0.5% | +0.6% | -5.1% | +4.5% | +0.5% | -0.0% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $22.32 | $22.44 | +0.5% | +0.7% | -5.4% | -3.4% | +0.6% | -5.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Van Tuyl ChristopherOff | Chief Legal Officer | Sell | 2,634 | $35.39 | $93K | 180,597 | — | — |
| Jun 15, 2026 | Pande AtulDir | — | Sell | 1,500 | $34.02 | $51K | 116,731 | +3.27% | — |
| May 28, 2026 | Fromkin Andrew J.Dir | — | Sell | 210,468 | $33.56 | $7.1M | 74,382 | -1.32% | -4.78% |
| May 28, 2026 | Fromkin Andrew J.Dir | — | Sell | 11,483 | $32.64 | $375K | 284,850 | -1.32% | -4.78% |
| May 20, 2026 | Pande AtulDir | — | Sell | 6,000 | $32.00 | $192K | 116,731 | -4.02% | +0.27% |
| May 1, 2026 | Susman Robert GrahamDir | — | Sell | 2,502 | $27.17 | $68K | 36,394 | +2.69% | +6.32% |
8-K · 2.02
!! High
Immunovant, Inc. -- 8-K 2.02: Earnings Results
May 20
8-K
Immunovant, Inc. -- 8-K Filing
Immunovant's registrational trial for IMVT-1402 in rheumatoid arthritis is fully enrolled with topline data expected mid-2026, positioning the company for potential FDA approval and commercialization.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 16,947,888 | $421M | — | Mar 2026 |
| 2 | Morgan Stanley | 9,692,770 | $246M | Added | Dec 2025 |
| 3 | Vanguard Portfolio Management Llc | 3,704,905 | $92M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,620,050 | $90M | New | Mar 2026 |
| 5 | Rtw Investments, Lp | 3,177,849 | $79M | — | Mar 2026 |
| 6 | Adar1 Capital Management, Llc | 2,679,010 | $67M | New | Mar 2026 |
| 7 | Woodline Partners Lp | 1,975,869 | $49M | — | Mar 2026 |
| 8 | Farallon Capital Management Llc | 1,546,000 | $38M | New | Mar 2026 |
| 9 | Aberdeen Group Plc | 1,160,762 | $29M | Reduced | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 893,678 | $22M | Added | Mar 2026 |
| 11 | Stempoint Capital Lp | 746,494 | $19M | New | Mar 2026 |
| 12 | Jennison Associates Llc | 700,464 | $18M | New | Dec 2025 |
| 13 | Candriam S.c.a. | 680,372 | $17M | New | Dec 2025 |
| 14 | Ubs Group Ag | 684,551 | $17M | Reduced | Mar 2026 |
| 15 | Northern Trust Corp | 672,774 | $17M | Added | Mar 2026 |
| 16 | Susquehanna International Group, Llp | 617,807 | $15M | Added | Mar 2026 |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 467,469 | $12M | Reduced | Dec 2025 |
| 18 | Trails Edge Capital Partners, Lp | 414,054 | $10M | Added | Mar 2026 |
| 19 | Pictet Asset Management Holding Sa | 380,842 | $10M | Reduced | Dec 2025 |
| 20 | Superstring Capital Management Lp | 357,606 | $9M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$5.77B
Enterprise Value
$5.06B
P/E (TTM)
-13.71x
Forward P/E
—
PEG Ratio
-0.14x
P/B
8.16x
P/S
—
P/FCF
-15.33x
EV/EBITDA
—
Shares Out
151.6M
Financials (TTM)
Revenue
$0
Net Income
-$505.6M
EBITDA
-$505.0M
Free Cash Flow
-$376.6M
Op Cash Flow
-$375.9M
EPS Basic
$-2.73
EPS Diluted
$-2.78
EPS Forward
$-2.57
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$776.2M
Total Liab.
$68.8M
Total Equity
$707.4M
Cash
$714.0M
LT Debt
$0
Book Value/Sh
$4.67
Debt/Equity
0.00x
Current Ratio
11.16
Quick Ratio
11.16
Returns & Growth
ROE
-41.9%
ROA
-39.3%
ROIC
-61.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
-45.2%
Price Returns
2W
+15.0%
1M
+22.7%
3M
+20.1%
6M
+37.9%
12M
+124.2%
Technicals
52W High
$38.10
52W Low
$14.69
50d MA
$30.19
200d MA
$24.83
RSI (14)
68.60
ATR (14)
$1.60
Beta
0.67
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$45.50
High
$50.00
Low
$41.00
Median
$45.50
Data updated apr 25, 2026 3:25pm
· Source: financialmodelingprep.com